JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from an underweight rating to a neutral rating in a research report sent to investors on Tuesday morning, Briefing.com Automated Import reports. JPMorgan Chase & Co. currently has $8.00 price objective on the stock.
TEVA has been the topic of a number of other research reports. Cowen set a $9.00 target price on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research note on Wednesday, August 7th. UBS Group set a $8.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a hold rating in a research note on Friday, August 16th. Raymond James dropped their price target on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an outperform rating on the stock in a research note on Thursday, August 8th. ValuEngine raised shares of Teva Pharmaceutical Industries from a buy rating to a strong-buy rating in a research note on Friday, November 8th. Finally, Gabelli raised shares of Teva Pharmaceutical Industries from a hold rating to a buy rating in a research note on Wednesday, October 16th. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $10.83.
Shares of TEVA stock traded up $0.83 during mid-day trading on Tuesday, reaching $10.20. The company’s stock had a trading volume of 29,023,199 shares, compared to its average volume of 26,805,626. The company’s 50 day simple moving average is $7.79 and its 200-day simple moving average is $8.74. Teva Pharmaceutical Industries has a 12-month low of $6.07 and a 12-month high of $22.83. The company has a quick ratio of 0.56, a current ratio of 0.89 and a debt-to-equity ratio of 1.62. The firm has a market capitalization of $10.68 billion, a PE ratio of 3.64, a price-to-earnings-growth ratio of 1.05 and a beta of 1.73.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, November 7th. The company reported $0.56 EPS for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.02). Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. The business had revenue of $4.26 billion during the quarter, compared to analysts’ expectations of $4.25 billion. As a group, research analysts anticipate that Teva Pharmaceutical Industries will post 2.26 EPS for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Interstate Bank bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $28,000. Pacer Advisors Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $32,000. AdvisorNet Financial Inc increased its position in shares of Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock worth $25,000 after purchasing an additional 1,525 shares during the last quarter. Kavar Capital Partners LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $35,000. Finally, Motco bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $28,000. 58.20% of the stock is owned by institutional investors.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: QQQ ETF
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.